With painkiller addiction on the rise.

Devising a better painkiller is certainly big business. Doctors wrote more than 200 million prescriptions for opioid medicines in america during 2009. Meanwhile, the amount of people entering substance abuse programs for opioid addiction elevated fivefold between 1998 and 2008, and a July 2010 statement from the united states Centers for Disease Control and Prevention points to painkillers as the leading reason behind fatal drug overdoses. However, not every ‘abuse-deterrent’ style has received a regulatory thumbs-up. June On 23, just a few days following the Oxecta approval, the FDA rejected due to manufacturing problems Remoxy. Remi Barbier, president and ceo of Pain Therapeutics in Austin, Texas, which developed the medication with Pfizer, says the firms are working to solve those issues now.) Picture: by Flickr user Be.Futureproof under Creative Commons..Shortly. AP26113 may also begin clinical development this quarter. We have outstanding momentum building through the entire Organization and every expectation that it will continue through the entire remainder of the year and the coming year. Merck Starts Submissions for Regulatory Approval of Ridaforolimus ARIAD’s partner, Merck, submitted a marketing authorization application for ridaforolimus with the European Medicines Agency on July 29, 2011. The submission marks the start of Merck’s global submission technique for ridaforolimus that includes European countries, the U.S., Canada, Asia-Pacific and Latin America and other key marketplaces around the world.